Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma - authors' reply

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 6, 2016, Pages 650-651

  Gounder, P P ^a   Bulkow, L R ^a   McMahon, B J ^a,b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN;

AGE DISTRIBUTION; ALASKA NATIVE; ANTIVIRAL THERAPY; CANCER RISK; ETHNIC DIFFERENCE; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE C; HUMAN; LETTER; LIVER CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEROLOGY; VIREMIA; VIRUS REPLICATION;

EID: 84981167133     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13730     Document Type: Letter

References (6)

1. Chen YC, Liaw YF. Letter: hepatitis B surface seroclearance does reduce the risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2016; 44: 210–1.
2. Gounder PP, Bulkow LR, Snowball M, et al. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 2016; 43: 1197–207.
3. Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133: 1452–7.
4. Ching LK, Gounder PP, Bulkow L, et al. Incidence of hepatocellular carcinoma according to hepatitis B virus genotype in Alaska native people. Liver Int 2016; doi: 10.1111/liv.13129. [Epub ahead of print].
5. Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192–9.
6. Yuen M-F, Sablon E, Yuan H-J, et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003; 37: 562–7.